An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells - PubMed (original) (raw)

. 2005 Dec;27(6):1625-32.

Affiliations

PMID: 16273219

An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells

Pedro Miguel Lacal et al. Int J Oncol. 2005 Dec.

Abstract

The vascular endothelial growth factor-A (VEGF-A) is a cytokine that promotes angiogenesis through the activation of two tyrosine kinase receptors, VEGFR-1 and VEGFR-2, on vascular endothelial cells. Moreover, several experimental evidences indicate that VEGF-A may also play a role in tumor progression by acting on neoplastic cells expressing VEGFRs. In this study we show that human melanoma cells that simultaneously produce VEGF-A and express VEGFRs exhibit a higher spontaneous ability to invade the extracellular matrix (ECM) than melanoma cells not expressing either VEGF-A or VEGFRs. Exposure of VEGFR expressing melanoma cells to exogenous VEGF-A further increases their ability to invade the ECM. Moreover, an inhibitor of VEGFR tyrosine kinase activity is able to abrogate VEGF-A-induced stimulation of ECM invasion. A cell clone (13443/N2) derived from a VEGF-A responsive melanoma cell line and expressing high levels of VEGFR-2 invades the ECM eight-fold more efficiently than a cell clone derived from the same cell line and expressing extremely low levels of the receptor. Exposure of 13443/N2 cells to VEGF-E, which selectively binds and activates VEGFR-2, increases their ability to invade the ECM. Finally, the expression of the VEGF-A mRNA antisense sequence in 13443/N2 cells markedly reduces the release of VEGF-A and ECM invasion. In conclusion, our data show for the first time that a VEGF-A-driven autocrine loop promotes human melanoma cell ability to invade the ECM, and strongly support the hypothesis that activation of VEGFR-2 plays a primary role in this process.

PubMed Disclaimer

Cited by

The Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) D16F7 Monoclonal Antibody Inhibits Melanoma Adhesion to Soluble VEGFR-1 and Tissue Invasion in Response to Placenta Growth Factor.
Atzori MG, Ceci C, Ruffini F, Scimeca M, Cicconi R, Mattei M, Lacal PM, Graziani G. Atzori MG, et al. Cancers (Basel). 2022 Nov 14;14(22):5578. doi: 10.3390/cancers14225578. Cancers (Basel). 2022. PMID: 36428669 Free PMC article.
Suppressing VEGF-A/VEGFR-2 Signaling Contributes to the Anti-Angiogenic Effects of PPE8, a Novel Naphthoquinone-Based Compound.
Hsu MJ, Chen HK, Lien JC, Huang YH, Huang SW. Hsu MJ, et al. Cells. 2022 Jul 5;11(13):2114. doi: 10.3390/cells11132114. Cells. 2022. PMID: 35805198 Free PMC article.
Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors.
Cristiani CM, Capone M, Garofalo C, Madonna G, Mallardo D, Tuffanelli M, Vanella V, Greco M, Foti DP, Viglietto G, Ascierto PA, Spits H, Carbone E. Cristiani CM, et al. Front Immunol. 2022 Jan 31;13:811131. doi: 10.3389/fimmu.2022.811131. eCollection 2022. Front Immunol. 2022. PMID: 35173725 Free PMC article.
Role of VEGFs/VEGFR-1 Signaling and its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models.
Ceci C, Atzori MG, Lacal PM, Graziani G. Ceci C, et al. Int J Mol Sci. 2020 Feb 18;21(4):1388. doi: 10.3390/ijms21041388. Int J Mol Sci. 2020. PMID: 32085654 Free PMC article. Review.
Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.
Atzori MG, Ceci C, Ruffini F, Trapani M, Barbaccia ML, Tentori L, D'Atri S, Lacal PM, Graziani G. Atzori MG, et al. J Cell Mol Med. 2020 Jan;24(1):465-475. doi: 10.1111/jcmm.14755. Epub 2019 Nov 23. J Cell Mol Med. 2020. PMID: 31758648 Free PMC article.

An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells - PubMed (original) (raw)